-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...